E2Mate

E2Mate

SCHEMBL628174

C[C@]12CC[C@@H]3c4ccc(OS(N)(=O)=O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 9/20 1.00
ABCC1 P33527 1/20 0.83
ABCC4 O15439 1/20 0.83
KDM4E B2RXH2 1/20 0.81
CA1 P00915 2/20 0.76
CA2 P00918 2/20 0.76
CA9 Q16790 2/20 0.76
LMNA P02545 4/20 0.75
HSD17B10 Q99714 4/20 0.75
ESR1 P03372 5/20 0.73
PGR P06401 2/20 0.73
AR P10275 2/20 0.73
SLC6A3 Q01959 2/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
ADORA3 P0DMS8 1/20 0.73
CHRM1 P11229 1/20 0.73
TBXA2R P21731 1/20 0.73
ADRA1A P35348 1/20 0.73
OPRM1 P35372 1/20 0.73
ATM Q13315 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
E2Mate SCHEMBL19272474 1.00 STS (1.00) STSABCC1ABCC4KDM4ECA1
E2Mate SCHEMBL5165269 1.00 STS (1.00) STSABCC1ABCC4KDM4ECA1
E2Mate SCHEMBL6866434 1.00 STS (1.00) STSABCC1ABCC4KDM4ECA1
E2Mate SCHEMBL5980613 1.00 STS (1.00) STSABCC1ABCC4KDM4ECA1
E2Mate SCHEMBL29924099 1.00 STS (1.00) STSABCC1ABCC4KDM4ECA1
E2Mate SCHEMBL5151234 1.00 STS (1.00) STSABCC1ABCC4KDM4ECA1
E2Mate SCHEMBL10070158 1.00 STS (1.00) STSABCC1ABCC4KDM4ECA1
Emate SCHEMBL7164522 0.93 STS (0.86) STSABCC1ABCC4KDM4ECA1
E2Mate SCHEMBL15940838 0.91 STS (0.83) STSABCC1ABCC4KDM4ECA1
SCHEMBL232796 0.91 ABCC4 (1.00) STSABCC1ABCC4KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119701013-A Estrogen-beta-cyclodextrin inclusion compound, preparation method thereof and tablets 浙江仙琚制药股份有限公司 2025-03-28 CN claimed
EP-2062569-B1 Vaginal delivery system BAYER OY (FI) 2011-05-11 EP claimed
US-20110097405-A1 ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-04-28 US claimed
EP-2249803-A2 ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM Bayer Schering Pharma Aktiengesellschaft (DE) 2010-11-17 EP claimed
US-20100285097-A1 VAGINAL DELIVERY SYSTEM BAYER OY (FI) 2010-11-11 US claimed
EP-2227220-A1 VAGINAL DELIVERY SYSTEM Bayer Schering Pharma Oy (FI) 2010-09-15 EP claimed
WO-2009101021-A2 ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-08-20 WO claimed
US-20090142313-A1 VAGINAL DELIVERY SYSTEM BAYER SCHERING PHARMA OY (FI) 2009-06-04 US claimed
WO-2009066006-A1 VAGINAL DELIVERY SYSTEM BAYER SCHERING PHARMA OY (FI) 2009-05-28 WO claimed
EP-2062569-A1 Vaginal delivery system Bayer Schering Pharma Oy (FI) 2009-05-27 EP claimed
EP-1100509-B1 USE OF BIOGENIC ESTROGEN SULFAMATES FOR HORMONE REPLACEMENT THERAPY SCHERING AG (DE) 2005-04-06 EP claimed
US-6841548-B2 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives SCHERING AG (DE) 2005-01-11 US claimed
EP-1456224-A2 INDUSTRIALLY APPLICABLE PROCESS FOR THE SULFAMOYLATION OF ALCOHOLS AND PHENOLS Schering Aktiengesellschaft (DE) 2004-09-15 EP claimed
US-20030171346-A1 Industrially applicable process for the sulfamoylation of alcohols and phenols SCHERING AG (DE) 2003-09-11 US claimed
WO-2003053992-A2 INDUSTRIALLY APPLICABLE PROCESS FOR THE SULFAMOYLATION OF ALCOHOLS AND PHENOLS SCHERING AKTIENGESELLSCHAFT (DE) 2003-07-03 WO claimed
CN-1404394-A Composition comprising a metal oxide and a metal oxide STERIX LTD (GB) 2003-03-19 CN claimed
US-20020061868-A1 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives STERIX LIMITED (GB) 2002-05-23 US claimed
US-6080735-A SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES JENAPHARM GMBH & CO. KG (DE) 2000-06-27 US claimed
EP-0889727-A1 SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY SCHERING AKTIENGESELLSCHAFT (DE) 1999-01-13 EP claimed
WO-1997033589-A1 SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY SCHERING AKTIENGESELLSCHAFT (DE) 1997-09-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061868-A1 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives ESRRA, ESR2, CYP19A1 STS 124/4885ABCC1 819/4885ABCC4 2078/4885
US-20030171346-A1 Industrially applicable process for the sulfamoylation of alcohols and phenols HSD17B11, ADH1C, ADH1A STS 5/4885ABCC1 4806/4885ABCC4 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.